Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.37 |
| ▸ | BAD | Q92934 | 1/20 | 0.37 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.37 |
| ▸ | PTGIR | P43119 | 1/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1118841 | 0.92 | NPSR1 (0.50) | S100A4ESR1ESR2NR3C2PTGIR | |
| SCHEMBL9960174 | 0.82 | GAA (0.43) | CES2CES1CA1CA2APP | |
| SCHEMBL9834275 | 0.79 | CES2 (0.41) | S100A4CES2CES1ESR1ESR2 | |
| SCHEMBL11870667 | 0.78 | CES2 (0.44) | CES2CES1TSHRCA1CA2 | |
| SCHEMBL11872550 | 0.78 | ESR1 (0.43) | ESR1ESR2CA1CA2APP | |
| SCHEMBL20560685 | 0.77 | CES2 (0.39) | S100A4CES2CES1ESR1ESR2 | |
| SCHEMBL11703895 | 0.77 | TSHR (0.37) | S100A4ESR1ESR2TSHRNR3C2 | |
| SCHEMBL31009210 | 0.77 | POLQ (0.45) | S100A4CES2CES1CA1CA2 | |
| SCHEMBL16026954 | 0.76 | ALDH1A1 (0.44) | CES2CES1TSHRNPSR1ALDH1A1 | |
| SCHEMBL28091134 | 0.76 | CES2 (0.42) | CES2CES1CA1CA2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| EP-3770148-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2021-01-27 | — | — | EP | disclosed |
| EP-1042277-B1 | NAPHTHALENE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6303649-B1 | FOR THERAPY AND PROPHYLAXIS OF ARTERIAL OBSTRUCTION, CEREBROVASCULAR DISEASE, HEPATIC CIRRHOSIS, ARTERIOSCLEROSIS, ISCHEMIC HEART DISEASE, RESTENOSIS, ISCHEMIC COMPLICATIONS AFTER CORONARY ANGIOPLASTY, HYPERTENSION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-16 | — | — | US | disclosed |
| US-4782071-A | Tetrasubstituted urea cholinergic agents | WARNER-LAMBERT COMPANY (US) | 1988-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | TACR1, TACR2, GPBAR1 | S100A4 4028/4885CES2 2077/4885CES1 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.